Innocan Pharma gets patent in India for Liposomal CBD Injection
Israel: Innocan Pharma Corporation has announced that it has been granted a patent in India covering a prolonged-release pharmaceutical formulation, utilizing liposomes to encapsulate cannabinoids.
This granted patent protects Innocan's synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of Synthetic CBD into the bloodstream. LPT-CBD received positive feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-IND meeting to advance its development as a non-opioid alternative for chronic pain management.
Developed jointly in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem, the liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of cannabinoids.
"We are thrilled to receive our first granted patent for our proprietary technology," said Iris Bincovich, Chief Executive Officer of Innocan Pharma. "This milestone highlights our innovation and we look forward to a series of anticipated global patent approvals."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.